Johnson & Johnson $JNJ Shares Sold by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 121,043 shares of the company’s stock after selling 1,256 shares during the period. SBI Securities Co. Ltd.’s holdings in Johnson & Johnson were worth $18,489,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $1,369,188,000. Pacer Advisors Inc. lifted its stake in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson in the second quarter worth approximately $401,420,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Johnson & Johnson by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock valued at $2,803,042,000 after buying an additional 2,129,612 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ opened at $193.76 on Wednesday. The business’s 50-day moving average is $184.79 and its 200-day moving average is $169.31. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $466.83 billion, a price-to-earnings ratio of 18.70, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Raymond James Financial raised their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, HSBC raised their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.